Federated Hermes Inc. Makes New $155,000 Investment in CryoPort, Inc. (NASDAQ:CYRX)

Federated Hermes Inc. bought a new position in CryoPort, Inc. (NASDAQ:CYRX) in the 1st quarter, according to its most recent disclosure with the SEC. The firm bought 25,491 shares of the company’s stock, valued at approximately $155,000. Federated Hermes Inc. owned 0.05% of CryoPort at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Readystate Asset Management LP lifted its position in shares of CryoPort by 91.6% in the 1st quarter. Readystate Asset Management LP now owns 500,344 shares of the company’s stock worth $3,042,000 after purchasing an additional 239,153 shares during the period. SBI Securities Co. Ltd. lifted its position in shares of CryoPort by 548,750.0% in the 1st quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company’s stock worth $67,000 after purchasing an additional 10,975 shares during the period. CWM LLC lifted its position in shares of CryoPort by 1,437.0% in the 1st quarter. CWM LLC now owns 11,328 shares of the company’s stock worth $69,000 after purchasing an additional 10,591 shares during the period. Rhumbline Advisers lifted its position in shares of CryoPort by 23.8% in the 1st quarter. Rhumbline Advisers now owns 78,320 shares of the company’s stock worth $476,000 after purchasing an additional 15,036 shares during the period. Finally, GAMMA Investing LLC lifted its position in shares of CryoPort by 4,434.6% in the 1st quarter. GAMMA Investing LLC now owns 14,556 shares of the company’s stock worth $89,000 after purchasing an additional 14,235 shares during the period. 92.90% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other CryoPort news, Director Robert J. Hariri sold 12,500 shares of the firm’s stock in a transaction dated Wednesday, May 28th. The shares were sold at an average price of $6.10, for a total transaction of $76,250.00. Following the completion of the sale, the director directly owned 8,061 shares in the company, valued at approximately $49,172.10. This trade represents a 60.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jerrell Shelton sold 16,344 shares of the firm’s stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $7.06, for a total transaction of $115,388.64. Following the sale, the chief executive officer owned 912,419 shares of the company’s stock, valued at approximately $6,441,678.14. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 490,447 shares of company stock valued at $3,337,198 in the last quarter. 10.10% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently commented on CYRX. Leerink Partnrs raised shares of CryoPort from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 6th. Stephens started coverage on shares of CryoPort in a research report on Tuesday, July 22nd. They set an “overweight” rating and a $13.00 price target for the company. Leerink Partners raised shares of CryoPort from a “market perform” rating to an “outperform” rating and set a $16.00 price target for the company in a research report on Wednesday, August 6th. KeyCorp raised shares of CryoPort from a “sector weight” rating to an “overweight” rating and set a $15.00 price target for the company in a research report on Wednesday, August 6th. Finally, Needham & Company LLC reissued a “buy” rating and set a $11.00 price target on shares of CryoPort in a research report on Thursday, May 8th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $12.00.

CryoPort Stock Down 7.8%

NASDAQ:CYRX opened at $7.56 on Monday. The firm has a market cap of $379.06 million, a P/E ratio of 5.68 and a beta of 1.88. The company has a debt-to-equity ratio of 0.51, a quick ratio of 5.24 and a current ratio of 5.56. CryoPort, Inc. has a fifty-two week low of $4.58 and a fifty-two week high of $9.66. The firm has a 50-day simple moving average of $7.20 and a two-hundred day simple moving average of $6.57.

CryoPort (NASDAQ:CYRX) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.09). The firm had revenue of $45.45 million for the quarter, compared to the consensus estimate of $41.74 million. CryoPort had a net margin of 37.21% and a negative return on equity of 10.48%. Analysts predict that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

CryoPort Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.